tbuckley/cabot-search huggingface dataset:
Corrigendum to “Engineering a sprayable and elastic hydrogel adhesive with antimicrobial properties for wound healing” [Biomaterials 139 (2017), 18080]
Authors: Nasim Annabi, Devyesh Rana, Ehsan Shirzaei Sani, Roberto Portillo-Lara, Jessie L Gifford, Mohammad M Fares, Suzanne M Mithieux, Anthony S Weiss
Journal: Biomaterials (2024)
Benchmarks of Success in Radiotherapy versus Systemic Therapy National Clinical Trials Network (NCTN) Randomized Controlled Trials Sponsored by the National Cancer Institute (NCI)
Authors: Nina N Sanford, Qian Shi, David M Hein, William A Hall
Journal: JNCI Journal of the National Cancer Institute (2024)

The National Clinical Trials Network (NCTN) is the largest government sponsored organization in the United States tasked with funding randomized controlled trials (RCTs) in oncology. It is unknown whether there are differences in study design by treatment modality. We evaluated differences in methodology between trials testing radiotherapy versus systemic therapy.
P102 Importance of the inflammation in adipose tissue as exacerbating factor of obesity-associated psoriasis
Journal: British Journal of Dermatology (2024)

Abstract Obesity is a risk factor for psoriasis. However, it is not necessarily detrimental when excess fat is stored in healthy adipose tissue. To identify pathogenic association between obesity and psoriasis, we investigated an obese mouse model of psoriasis induced by topical imiquimod or dermal interleukin (IL)-23 injection. Obese mice exhibited aggravated psoriatic dermatitis with pronounced systemic inflammatory responses when exposed to imiquimod. Notably, imiquimod-induced psoriatic dermatitis in obese mice significantly reduced fat mass. Further, pronounced monocyte–macrophage infiltration of perigonadal adipose tissue, increased expression of genes linked to inflammation, and upregulation of cell death-associated molecules were evident in obese mice treated with imiquimod compared with their lean counterparts. In contrast, IL-23 injection could induce similar features of psoriatic inflammation in obese and lean mice, without causing adipose tissue destruction or a systemic increase in inflammatory mediators. Obese adipose tissue of mice with imiquimod-induced psoriatic inflammation featured genetic and epigenetic changes in adipocytes and shifts in macrophage compartments towards disturbed homeostasis using multiomic single-nucleus sequencing targeting RNA and accessible chromatin. Our study demonstrates that disrupted homeostasis in obese adipose tissue amplifies the systemic manifestations of psoriasis, highlighting the potential for developing interventions to control obesity-associated exacerbation of psoriasis.
P48 Maintenance response of guselkumab in the Chinese population: an interim analysis of an observational study
Journal: British Journal of Dermatology (2024)

Abstract Maintenance treatment with biologics is recommended for the treatment of moderate-to-severe psoriasis; however, treatment withdrawal occurs frequently in the real world. In a post-approval commitment (PAC) study (NCT04914429), guselkumab demonstrated efficacy in Chinese patients with moderate-to-severe plaque psoriasis. Here, we report interim analysis results from the observational post-PAC study evaluating health-related quality of life (HRQoL) and psoriasis relapse within 24 weeks following guselkumab withdrawal. This prospective, observational study enrolled patients who achieved a psoriasis area and severity index (PASI) 75 response at Week 44 in the PAC study. In the framework of a decentralized clinical trial design, patients utilized an electronic patient-reported outcome system to report on HRQoL, psoriasis status, and administration of systemic treatment for psoriasis. HRQoL was assessed by the dermatology life quality index (DLQI) at baseline, then every 12 weeks through Week 48. Psoriasis relapse was defined as the initiation of a new systemic treatment for psoriasis. Off-treatment duration (OTD) was defined as the time between the last guselkumab administration at Week 44 in the PAC study and the date of the first dose of any systemic treatment for psoriasis, loss to follow-up, death, or end of the study. A planned interim analysis was conducted when all patients had completed questionnaires 24 weeks after guselkumab withdrawal. The data cut-off (DCO) date was 3 June 2024. A total of 243 patients were enrolled. As of DCO, two patients withdrew from the study due to loss of follow-up. Most patients were male [n = 194 (79.8%)] and mean [standard deviation (SD)] age was 41.2 (12.3) years. At baseline, nearly all patients had PASI &amp;lt;3 [94.2% (229/243)] and Investigator’s Global Assessment 0/1 [91.4% (222/243)]. DLQI scores gradually increased after guselkumab withdrawal, from a mean (SD) of 4.8 (4.4) on the index date to 5.2 (4.6) at Week 12 and 7.2 (6.0) at Week 24 [mean (SD) change: 0.4 (4.5) at Week 12; 2.5 (6.2) at Week 24]. Overall, 5.8% (14/241) of patients had a psoriasis relapse. The mean (SD) OTD was 157.6 (1.1) days; the median OTD was not reached. Patients in this post-PAC study in China experienced gradual deterioration of HRQoL after guselkumab withdrawal. Only a small proportion of patients experienced a psoriasis relapse during 24 weeks of follow-up, suggesting treatment response was generally maintained after guselkumab withdrawal. Results from the planned interim analysis were not conclusive due to the limited duration of follow-up; long-term data analysis will be conducted upon study completion at Week 48.
P46 Long-term efficacy of biologic agents and apremilast in scalp psoriasis: a real-life, cohort study
Journal: British Journal of Dermatology (2024)

Abstract Scalp psoriasis affects up to 80% of patients and is the initial manifestation of the disease in ∼25% of cases, with significant psychosocial burden. In our real-life cohort study, we compared the long-term efficacy of the available biologic agents and apremilast from 52 to 78 weeks of treatment between March 2019 and March 2024. Overall, 359 patients from the First Dermatology Department of Thessaloniki, Greece were recruited. Descriptive statistics and ANOVA were used (SPPSS package; statistical significance: P &amp;lt; 0.05). After 1 year of treatment (52 weeks), complete clearance of scalp psoriasis (PSSI 0/1) was achieved or maintained in 96% (24/25) with infliximab, 95.57% (44/46) with guselkumab, 93.94% (31/33) receiving ixekizumab, 93.10% (27/29) with ustekinumab, 93.94% (31/33) with secukinumab, 92.59% (25/27) with certolizumab pegol, 91.83% (45/49) of patients receiving risankizumab, 90.32% (28/31) with brodalumab, 86.21% (25/29) with apremilast, 86.21% (25/29) with etanercept, and 85.71% (24/28) with adalimumab. At 62 weeks, biological agents and apremilast maintained their efficacy: 92.0% (23/25) with infliximab; 97.83% (45/46) with guselkumab; 96.97% (32/33) receiving ixekizumab; 89.66% (26/29) with ustekinumab; 96.97% (32/33) with secukinumab; 88.89% (24/27) with certolizumab pegol, 93.88% (45/49) of patients receiving risankizumab, 96.77% (30/31) with brodalumab, 93.10% (25/29) with apremilast, 82.76% (24/29) with etanercept, and 85.71% (24/28) with adalimumab. Finally, at 78 weeks, clearance rates were maintained at high levels: 88.0% (22/25) with infliximab, 95.65% (44/46) with guselkumab, 100.00% (33/33) receiving ixekizumab, 93.10% (27/29) with ustekinumab, 93.94% (31/33) with secukinumab, 85.19% (23/27) with certolizumab pegol, 97.96% (48/49) of patients receiving risankizumab, 93.55% (29/31) with brodalumab, 86.21% (25/29) with apremilast, 89.65% (26/29) with etanercept, 92.86% (26/28) with adalimumab. No treatment among the agents demonstrated statistically significant superiority at any time point after 52 weeks of therapy (P &amp;lt; 0.05). From Week 52 to Week 78, we found that ∼90% of patients responded to the treatment, thus confirming the long-term efficacy of biological agents and apremilast. At 78 weeks, all treatments could maintain clinical improvement in all patients. Indeed, the proportion of patients achieving PSSI 0/1—even with initially less effective drugs—increased progressively achieving complete clearance or near-complete clearance in 86.21% of patients at Week 78. This study, therefore, confirms what has been previously reported in the literature regarding the sustained efficacy of anti-IL17 and anti-IL23, but also the sustained efficacy, albeit slower than the other classes of biological agents, of anti-TNFα agents and apremilast.
P57 Cross-sectional application of the dermatologist-centred screening tool, looking for axial psoriatic arthritis in patients with severe plaque psoriasis
Journal: British Journal of Dermatology (2024)

Abstract Psoriasis is a chronic, inflammatory and immune-mediated systemic disease that primarily affects the skin and joints. In ∼70% of cases, the skin disease precedes joint involvement, and it is estimated that approximately one-third of patients with psoriatic disease will develop psoriatic arthritis (PsA) over the course of their disease. Researchers often seek to establish good screening tools or even biomarkers that can help the clinical dermatologist in this assessment, improving the window of opportunity for action. Most of the validated tools, such as PEST and PASE, despite their excellent performance, do not consider the axial domain of PsA. We conducted a cross-sectional study on our cohort of severe psoriasis patients from our outpatient clinic, applying the dermatologist-centred screening (DCS) questionnaire. PsA was defined by CASPAR criteria. Statistical analysis was performed in SPSS 20.0. The study underwent ethical review and was approved: average age of 50.84 years, with a slight predominance of females (53.2%). The average duration of the disease was 15.89 years. Mean PASI and body surface area (BSA) were, respectively, 16.65 and 20.88%. Hundred and fifty-eight patients were studied: average age of 50.84 years, with a slight predominance of females (53.2%). The average duration of the disease was 15.89 years. Mean PASI and BSA were, respectively, 16.65 and 20.88%. Fifty of the 158 patients were diagnosed with PsA (31.6%). In the sample, 35 patients had positive DCS. Of these 35, in fact, 25 (71.4%) had PsA. Having positive DCS implies a prevalence at least three times higher than having PsA (prevalence ratio: 3.254, P &amp;lt; 0.0001, 95% confidence interval = 2.195–4.824). Among the 25 with positive DCS, 10 patients had low back pain at the end of the night, sometimes even being woken up by the pain; maintaining it during the morning, associated with stiffness for at least 30 min; in addition to relief with movement and stretching. Of these 10, 7 (14% of patients with PsA and 28% of all with positive DCS) had a confirmed diagnosis of axial PsA, supported by evaluation by a board-certified rheumatologist, in addition to complementary exams (all with positive magnetic resonance imaging showing sacroiliitis). The ATTRACT study studied 365 patients; selecting through DCS 124. Of these, 36 (29%) confirmed a diagnosis of Axial PsA and 21 (16.9%) had peripheral PsA, without axial involvement. DCS appears to be a practical, quick and easy tool to perform in clinical practice, correctly selecting patients for better evaluation by a rheumatologist, probably contributing to a better diagnosis. The limitations of this work are the cross-sectional design and small sample.
P31 Global epidemiology of psoriasis: Global Psoriasis Atlas 2024 update
Journal: British Journal of Dermatology (2024)

Abstract The WHO has highlighted the necessity of gaining a deeper understanding of the global burden of psoriasis. In response to this need, the Global Psoriasis Atlas was established to conduct comprehensive research into the global prevalence and incidence of psoriasis. We aimed to systematically review and present up-to-date data on the incidence of psoriasis, as well as to quantify its prevalence at global, regional, and country-specific levels. Literature searches were updated from 2019 to January 2024, resulting in 48 new studies. Among these, 13 studies reported incidence data, 7 reported only incidence, 6 reported both prevalence and incidence, and the remaining 35 studies reported only prevalence. In total, our updated prevalence analysis included 170 population-based epidemiological studies. A Bayesian hierarchical linear mixed model was employed to estimate the global, regional, and country-specific prevalence of psoriasis. Countries were mapped according to the global burden of disease (GBD) classification, considering geography and income. The data were fitted to a statistical model using Bayesian inference, sampling from a posterior distribution through a Hamiltonian Markov chain Monte Carlo method implemented in the RStanArm package in R (version 4.4.0). The updated review incorporated data from eight new countries and expanded to cover two additional GBD global regions. We observed a global increase in the prevalence of psoriasis, with some variations attributed to the significant expansion with the update of certain very sparse datasets. The crude lifetime prevalence for adults in high-income countries increased from 1.12% [95% confidence interval (CI): 0.39, 2.79] to 1.40% (95% CI: 0.52, 3.25). In the Latin America and Caribbean super-region, prevalence rates appear to have slightly decreased, but this finding is based on a very low evidence base, with no studies on psoriasis prevalence included from Caribbean countries. Most of the newly added studies were from high-income countries, with 70% originating from Western Europe, North America, and high-income Asian countries. The incidence of psoriasis varied from 23.14 per 100 000 person years in Taiwan to 321.0 per 100 000 person years in Italy. The incidence of psoriasis was higher in adults than in children. Seventy-six per cent of countries worldwide lack data on the epidemiology of psoriasis. The prevalence of psoriasis is higher in adults compared with children. Additionally, the distribution of psoriasis varies geographically, with higher frequency observed in high-income countries and regions with older populations. These estimates can assist countries and the international community in making informed public health decisions regarding the appropriate management of psoriasis and in monitoring changes over time.
P119 Quality of life assessment in psoriasis patients: experiences from a dermatology day hospital
Journal: British Journal of Dermatology (2024)

Abstract The aim of the study was to determine the severity of psoriasis and the associated quality of life in patients with psoriasis who attended the dermatology day hospital for treatment. In this retrospective study, adults with different severities and subtypes of psoriasis were enrolled. The study included patients who were treated in the day hospital for more than 7 days and whom Affected body surface area (BSA), psoriasis area and severity index (PASI) and Dermatology Life Quality Index (DLQI) results were available. The BSA, PASI and DLQI were acquired before and after received treatment. Additional information about received therapy also was collected. Based on DLQI result, patients were divided as follows: 0–1 (no effect on patient’s life), 2–5 (small effect), 6–10 (moderate effect), 11–20 (very large effect), 21–30 (extremely large effect), before and after treatment. All data were summarized using MS Excel and analysed with IBM SPSS 25. The changes in BSA, PASI and DLQI after treatment were calculated and used to acquire Spearman’s correlation coefficients. The DLQI trend changes post-treatment in the corresponding groups were evaluated using crosstabs. Altogether 62 adult patients with psoriasis were enrolled—41.9% (n = 26) men, 58.1% (n = 36) women. The mean age was 51.26 years (range from 17 to 75 years). The average number of days spent in a Dermatology Day hospital was 18 days (range from 9 to 28 days). Upon admission to the hospital, based on the PASI scores 45.2% (n = 28) of patients met the criteria for mild psoriasis and 54.9% (n = 34) met the criteria for moderate-to-severe psoriasis. However, upon discharge from the hospital 62.9% (n = 39) of patients met the criteria for mild psoriasis and 37.1% (n = 23) met the criteria for moderate-to-severe psoriasis. 40.3% (n = 25) of patients in the day hospital received therapy with methotrexate, and 77.4% (n = 48) received Nb UVB phototherapy. There were no statistically significant correlations found between BSA and DLQI (P = 0.051) and PASI and DLQI (P = 0.092). From all included patients the DLQI 0-1 group pre-treatment was 3.2%, post-treatment increased to 12.9%, in 2–5 group from 12.9% increased to 32.3%, in 6–10 group from 29.0% increased to 32.3%, in 11–20 group from 40.3% decreased to 17.7%, in 21–30 group from 14.5% decreased to 4.8%. Although a statistically significant connection between quality-of-life index and BSA, PASI results was not determined, a decreasing trend in patients with very large effect and extremely large effect on quality of life after receiving treatment was established. Overall improvement in the patients’ quality of life was observed.
P24 Aminoacyl-tRNA synthetases: hidden players in psoriasis pathogenesis
Journal: British Journal of Dermatology (2024)

Abstract Over the past two decades, immune cells have been considered the main driver of psoriasis, while keratinocytes are thought to be an executor in response to immune cells. But most recent advance indicates that keratinocytes might be also involved in the relapse of psoriasis. Our group has focused on the epidermis and its immune microenvironment for a long time. In our previous study, the proteomic analysis of the epidermis in psoriatic patients and normal individuals revealed that several members of ARSs family were significant upregulation. Aminoacyl-tRNA synthetase is a family of enzymes that play a fundamental role in protein translation. Most mammalian cytoplasmic ARSs have acquired noncatalytic domains through evolution. We investigate that glycyl-tRNA synthetase induces psoriasis-like skin lesions by promoting skin inflammation and facilitating vascular endothelial cell angiogenesis. Moreover, inhibition of epidermal isoleucyl-tRNA synthetase ameliorates psoriasis-like skin lesions via JAK2/STAT3/CXCL16 signalling pathway. Our data provide insight into the noncanonical function of aminoacyl-tRNA synthetase in the pathogenesis of psoriasis. Topical medication that blocks or reduces related members might be effective and provide an approach to control limited psoriasis.
P36 Gut dysbiosis in severe plaque psoriasis: findings of a case-control study in southern Brazil
Journal: British Journal of Dermatology (2024)

Abstract Background Gut dysbiosis may play a role in immune-mediated diseases. There is a growing interest in understanding microbiome influence in psoriasis. Objectives To study the gut microbiome in patients with severe plaque psoriasis, when compared with individuals without psoriasis. In parallel, to evaluate the differences in the gut microbiome of individuals with psoriasis, with and without psoriatic arthritis. Methods V3/V4 16S rRNA gene sequencing and bioinformatic analyses were performed with the total DNA extracted from the stool samples of 30 patients with severe plaque psoriasis and 30 age, gender and body mass index-matched controls from the same geographic location. Psoriatic Arthritis (PsA) was defined by CASPAR criteria. All patients were seen by a board-certified rheumatologist. We excluded patients with other immunomediated or autoimmune diseases, previously related to gut dysbiosis. Also excluded were patients with neoplasias or a previous history of gastrointestinal bypass. Patients were not in systemic treatment for psoriasis and also had not received antibiotics or probiotics in the past 3 months. Results Sixty individuals were studied. No difference in alpha-diversity was documented between the groups (P &amp;gt; 0.05). Beta-diversity analysis showed different clustering of the gut microbiome in severe plaque psoriasis when compared with controls (P = 0.031). Adjusted differential abundance showed an increased expression of Sutterelacea family (P &amp;lt; 0.05) and Sutterella genus (P &amp;lt; 0.01) in the psoriasis group. When comparing patients with and without joint disease (15 PsO × 15 PsA), it was not possible to document differences in terms of alpha or beta diversity. However, patients with established psoriatic arthritis showed higher expression of the Bacteroidacea family (P = 0.02) and Bacterioides genus (P = 0.02). Conclusions It was possible to demonstrate a different pattern of gut microbiome among those with severe plaque psoriasis, when compared with controls. There was a significantly greater expression of the genus Sutterella among patients, which may represent a sign of dysbiosis related to psoriasis. In parallel, there were no statistically significant differences in alpha and beta diversity between patients with joint disease when compared with those without psoriatic arthritis. However, a hallmark in these patients was the greater expression of the genus Bacterioides, like previous studies. Reduction of Akkermansia and Ruminoccocus, previously related to psoriatic disease, were not verified in our sample. Perhaps due to low reading in both groups. This paper is one of the few Brazilian studies and brings insights into microbiome and psoriasis. Microbiome deserves our attention, especially since it brings different opportunities for intervention, although there are still many key points to be confirmed with prospective studies.